Topic: Patients with limited metastases benefit from metastasis-directed therapy - Belgium took the lead in this new and promising approach.
It is with great pleasure that we announce the 2022 BRAVO Symposium to be held in Brussels on Friday March 18th.
BRAVO and BeMedTech will bring together the Belgian Radiation Oncology community in a live and in-person format that builds on the success of our 2018 symposium. This year, we continue our mission to increase awareness of radiation oncology as a safe and modern treatment method of cancer.
Studies on radiotherapy cost-effectiveness in the treatment of lung cancer have been carried out both in the European and in the Belgian context. A large comparative study published in 2020 in the Lancet Oncology Review shows annual expenditure for Belgian radiotherapy corresponding to 6.4% of the overall expenditure of the total oncology budget, lower than the European average of 7.8%.
This article is only available in Dutch: original article.
In patients with prostate cancer who have a high risk of pelvic nodal disease, the use of elective whole pelvis radiotherapy is still controversial. Two large, randomised, controlled trials (RTOG 9413 and GETUG-01) did not show a benefit of elective whole pelvis radiotherapy over prostate-only radiotherapy. In 2020, the POP-RT trial established the role of elective whole pelvis radiotherapy in patients who have more than a 35% risk of lymph node invasion (known as the Roach formula). POP-RT stressed the importance of patient selection. In patients with cN1 (clinically node positive) disease or...
In 2020, 4,000 fewer cancer diagnoses were made in Belgium than expected, but the catching-up is hopeful05 Jul, 2021
Association of survival and local radiotherapy to the bladder versus chemotherapy alone for patients with metastatic urothelial carcinoma (mUC)15 Feb, 2021
Limited data exists on the role of local therapy for metastatic urothelial carcinoma of the bladder (mUC). Large database analysis have inherent limitations but can shed light on survival outcomes in a real-world population and in scenarios not easily studied in a randomized fashion. We hypothesized that in the NCDB, radiotherapy (RT) to the bladder plus chemotherapy (CT) would be associated with improved overall survival (OS) vs CT alone.
We queried the NCDB for newly diagnosed mUC cases (cT1-4 N0-3 M1) from 2004-2015 treated with CT alone vs CT plus RT to ≥ 45 Gy to the bl...
This article is only available in Dutch: original article
This article is only available in Dutch: original press release
Authors (in alphabetical order):
Alex De Caluwé, Institut Jules Bordet Katrien Erven, Iridium Kankernetwerk Carine Kirkove, Cliniques Universitaires Saint-Luc Vincent Remouchamps, CHU UCL Namur Liv Veldeman, UZ Gent Caroline Weltens, UZ Leuven
1 BENEFIT OF BREAST RADIOTHERAPY
Curative treatment for breast cancer consists of surgery, radiotherapy and systemic treatments such as chemotherapy, antihormonal therapy and targeted agents. The local treatment options are breast conserving treatment, consisting of breast sparing surgery followed by radiotherapy, and mastectomy with or without radio...
Breast cancer is a disease that affects about 1 in 9 women in Belgium before the age of 75, but it is nowadays a highly curable disease for a majority of people. Radiotherapy plays an essential role in the treatment of breast cancer. When the breast is preserved during surgery, the addition of radiotherapy leads to a clear reduction in the risk of local relapse, i.e. relapse in the treated breast or the draining lymph nodes. For every 4 local relapses prevented, 1 breast cancer death can be prevented. This survival benefit is also seen after mastectomy, but only in lymph node positive patients...